boronic acid 4-bromophenyl monoester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: boronic acid 4-bromophenyl monoester
• 英文别名: p-bromophenylboric acid；4-bromophenylboric acid；4-Bromophenyl-boric acid；(4-bromophenoxy)boronic acid
• 化学式: C₆H₆BBrO₃
• 分子量: 216.827
• InChiKey: PLKNDWWRTRLBKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基二乙醇胺 、 boronic acid 4-bromophenyl monoester 在 sodium methylate 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 4-溴苯硼酸N-甲基二乙醇胺酯
  参考文献：
  名称：

  N-ARYL-SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP1375496B1

文献信息

• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的羧酰胺化合物，其中A、B、W、X、Y、Z、R1、R2、R3和k的基团和残基具有权利要求1中所给出的含义。此外，本发明还涉及制备上述羧酰胺化合物的方法，以及含有本发明所述至少一种羧酰胺的制药组合物。基于它们的MCH受体拮抗活性，本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
  申请人：——

  公开号：US20020019429A1

  公开（公告）日：2002-02-14

  The present invention is directed to compound of the formula I: 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, and 2 are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.

  本发明涉及公式I的化合物：1其中R1、R2、R3、R4、R5、X、Y和2如此定义。这些化合物通过与一定量的本发明化合物接触来抑制金属蛋白酶的活性。
• Metalloproteinase inhibitors, pharmaceutical compositions containing
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06008243A1

  公开（公告）日：1999-12-28

  The present invention is directed to compound of the formula I: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y, and ##STR2## are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.

  本发明涉及式I的化合物：##STR1## 其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、X、Y和##STR2##如本文所定义。这些化合物通过将发明化合物的有效量与金属蛋白酶接触来抑制金属蛋白酶的活性。
• Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06174915B1

  公开（公告）日：2001-01-16

  The present invention is directed to compound of the formula I: wherein R1, R2, R3, R4, R5, X, Y, and  are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.

  本发明涉及化合物I的配方，其中R1、R2、R3、R4、R5、X、Y和β如下所定义。这些化合物通过将发明化合物的有效量与金属蛋白酶接触来抑制金属蛋白酶的活性。
• CYCLOALKYLAMINE DERIVATIVES
  申请人：Marumoto Shinji

  公开号：US20120295943A9

  公开（公告）日：2012-11-22

  Provided is a therapeutic agent for hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like, which has a CaSR activating (agonist) action. A compound represented by the following general formula (1): [wherein, Ar which is a partial structure in the general formula (1) represents a phenyl group or a naphthyl group; R 1a and R 1b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; R 2a and R 2b are the same or different from each other, and represent a hydrogen atom, a halogeno group, or the like; A represents a single bond, an oxygen atom, or the like; B represents a single bond, a C1-C4 alkanediyl group, or the like; Z represents a carboxyl group or a tetrazolyl group; and m represents an integer of 1 to 3] or a pharmacologically acceptable salt thereof.

  提供了一种治疗甲状旁腺功能亢进、肾性骨营养不良、高钙血症等疾病的治疗剂，具有CaSR激活（激动剂）作用。该化合物由以下通式（1）表示：[其中，通式（1）中的部分结构Ar表示苯基或萘基；R1a和R1b相同或不同，表示氢原子，卤素基团或类似物；R2a和R2b相同或不同，表示氢原子，卤素基团或类似物；A表示单键，氧原子或类似物；B表示单键，C1-C4烷二基基团或类似物；Z表示羧基或四唑基；m表示1至3的整数]或其药学上可接受的盐。